Nasdaq · CIK 0001824293
GRI GRI Bio, Inc.
Insider trading from SEC Form 4. Last filing Sep 22, 2025.
In brief
GRI Bio, Inc. (GRI) has 25 SEC Form 4 filings on file from 7 insiders, the latest filed on Sep 22, 2025. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
Last 90 days
Signals
Open-market buys and sells at GRI Bio, Inc., scored.
Transactions
Every row filed, 25 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 18, 2025 | Vipin Chaturvedi Chief Scientific Officer | AGrant or award Stock Option (Right to Buy)derivative | +43,222 | $0.00 | $0 | 43,222 | Sep 22, 2025 |
| Sep 18, 2025 | Leanne Kelly Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +43,222 | $0.00 | $0 | 43,222 | Sep 22, 2025 |
| Sep 18, 2025 | David Leslie Szekeres director | AGrant or award Stock Option (Right to Buy)derivative | +39,897 | $0.00 | $0 | 39,897 | Sep 22, 2025 |
| Sep 18, 2025 | Roelof Rongen director | AGrant or award Stock Option (Right to Buy)derivative | +23,605 | $0.00 | $0 | 23,605 | Sep 22, 2025 |
| Sep 18, 2025 | Camilla Simpson V director | AGrant or award Stock Option (Right to Buy)derivative | +23,605 | $0.00 | $0 | 23,605 | Sep 22, 2025 |
| Sep 18, 2025 | Walter Marc Hertz Chief Executive Officer | AGrant or award Stock Option (Right to Buy)derivative | +103,067 | $0.00 | $0 | 103,067 | Sep 22, 2025 |
| Sep 18, 2025 | David Charles Baker director | AGrant or award Stock Option (Right to Buy)derivative | +23,605 | $0.00 | $0 | 23,605 | Sep 22, 2025 |
| Aug 26, 2025 | David Leslie Szekeres director | AGrant or award Stock Option (Right to Buy)derivative | +10,276 | $0.00 | $0 | 10,276 | Aug 27, 2025 |
| Aug 26, 2025 | Walter Marc Hertz Chief Executive Officer | AGrant or award Stock Option (Right to Buy)derivative | +26,688 | $0.00 | $0 | 26,688 | Aug 27, 2025 |
| Aug 26, 2025 | Roelof Rongen director | AGrant or award Stock Option (Right to Buy)derivative | +5,994 | $0.00 | $0 | 5,994 | Aug 27, 2025 |
| Aug 26, 2025 | Camilla Simpson V director | AGrant or award Stock Option (Right to Buy)derivative | +5,994 | $0.00 | $0 | 5,994 | Aug 27, 2025 |
| Aug 26, 2025 | Leanne Kelly Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +11,854 | $0.00 | $0 | 11,854 | Aug 27, 2025 |
| Aug 26, 2025 | Vipin Chaturvedi Chief Scientific Officer | AGrant or award Stock Option (Right to Buy)derivative | +11,854 | $0.00 | $0 | 11,854 | Aug 27, 2025 |
| Aug 26, 2025 | David Charles Baker director | AGrant or award Stock Option (Right to Buy)derivative | +5,994 | $0.00 | $0 | 5,994 | Aug 27, 2025 |
| Aug 13, 2025 | David Charles Baker director | AGrant or award Stock Option (Right to Buy)derivative | +4,527 | $0.00 | $0 | 4,527 | Aug 14, 2025 |
| Aug 13, 2025 | David Leslie Szekeres director | AGrant or award Stock Option (Right to Buy)derivative | +7,545 | $0.00 | $0 | 7,545 | Aug 14, 2025 |
| Aug 13, 2025 | Roelof Rongen director | AGrant or award Stock Option (Right to Buy)derivative | +4,527 | $0.00 | $0 | 4,527 | Aug 14, 2025 |
| Aug 13, 2025 | Camilla Simpson V director | AGrant or award Stock Option (Right to Buy)derivative | +4,527 | $0.00 | $0 | 4,527 | Aug 14, 2025 |
| Jan 23, 2025 | David Charles Baker director | AGrant or award Stock Option (Right to Buy)derivative | +30,297 | $0.69 | $21k | 30,297 | Jan 24, 2025 |
| Jan 23, 2025 | Vipin Chaturvedi Chief Scientific Officer | AGrant or award Stock Option (Right to Buy)derivative | +43,319 | $0.69 | $30k | 43,319 | Jan 24, 2025 |
| Jan 23, 2025 | Roelof Rongen director | AGrant or award Stock Option (Right to Buy)derivative | +30,297 | $0.69 | $21k | 30,297 | Jan 24, 2025 |
| Jan 23, 2025 | David Leslie Szekeres director | AGrant or award Stock Option (Right to Buy)derivative | +51,937 | $0.69 | $36k | 51,937 | Jan 24, 2025 |
| Jan 23, 2025 | Camilla Simpson V director | AGrant or award Stock Option (Right to Buy)derivative | +30,297 | $0.69 | $21k | 30,297 | Jan 24, 2025 |
| Jan 23, 2025 | Walter Marc Hertz Chief Executive Officer | AGrant or award Stock Option (Right to Buy)derivative | +129,730 | $0.69 | $89k | 129,730 | Jan 24, 2025 |
| Jan 23, 2025 | Leanne Kelly Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +43,319 | $0.69 | $30k | 43,319 | Jan 24, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- David Charles Bakerdirector
- Vipin ChaturvediChief Scientific Officer
- Walter Marc HertzChief Executive Officer
- Leanne KellyChief Financial Officer
- Roelof Rongendirector
- Camilla Simpson Vdirector
- David Leslie Szekeresdirector
Questions about GRI
Answered from the filings on this page, as of the latest one.
Are insiders buying GRI?
No. In the last 90 days no insider at GRI Bio, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade GRI on the open market?
No open-market trade has been scored at GRI Bio, Inc.. The latest Form 4 on file was filed on Sep 22, 2025 and holds grants, exercises or other rows that are not market trades.
How many insiders file Form 4 at GRI Bio, Inc.?
7 people have filed a Form 4 at GRI Bio, Inc., among them David Charles Baker (director), Vipin Chaturvedi (Chief Scientific Officer), Walter Marc Hertz (Chief Executive Officer). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.